| Literature DB >> 35385210 |
Nishitha R Pillai1, Dana Miller2, Grace Bronken2, Amrita Kahlon Salunke3, Anjali Aggarwal1.
Abstract
Hardikar syndrome (HS) is a MED12-related ultra-rare multiple congenital malformation syndrome known to affect the gastrointestinal, cardiac, and genitourinary systems among other features including cleft lip/palate and pigmentary retinopathy. Only 10 patients affected with HS have been previously described in literature, of which seven were molecularly confirmed. We report a 20-year-old and a 13-month-old patient with HS diagnosed by exome sequencing bringing the total number of clinically diagnosed cases to 12 and MED12 associated to 9. We describe previously unreported molecular and clinical findings associated with HS and review all reported cases to permit prompt diagnosis, appropriate management, and genetic counseling of HS patients.Entities:
Keywords: Hardikar syndrome; MED12; X inactivation; aneurysm; cholangiocarcinoma
Mesh:
Substances:
Year: 2022 PMID: 35385210 PMCID: PMC9324214 DOI: 10.1002/ajmg.a.62756
Source DB: PubMed Journal: Am J Med Genet A ISSN: 1552-4825 Impact factor: 2.578
FIGURE 1Craniofacial features of P1 (a) Short forehead, low anterior hairline, long eyelashes, thick and arched eyebrows, low hanging columella, short philtrum, thin upper lip, broad mouth, and prominent chin. (1b) and (1c) Low‐set ears, overfolded superior helix, bilateral preauricular pits, and short neck. Craniofacial features of P2 showing (2a) Broad forehead, deep set eyes, telecanthus, and cleft lip s/p repair. (2b) Low set posteriorly rotated ears, ear pit near superior helix, overfolded superior helix, hypoplastic crux helix and ear lobe. (2c) Low set, posteriorly rotated ears, overfolded superior helix, ear pit near superior helix, underdeveloped antihelix, ear lobe and crux helix
Phenotypic and genotypic features present in all Hardikar patients reported to date
| Cases | Hardikar et al. ( | Cools and Jaeken ( | Maluf et al. ( | Poley and Proud ( | Li et al. ( | Current patients | Percentage of individuals affected | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P1 | P2 | P1 | P2 | P3 | P6 | P7 | P1 | P2 | NA | ||||
| Age at diagnosis | 11 years | 2 years | 1 year | 12 months | 7 years | 1 week | 14 months | 1 year | 8 months | 19 months | 20 years | 13 months | NA |
| Genotype (variant in | NA | NA | c.5111G>A; p.W1704* | NA | c.4903_4906del insCCAGCA; p.V1635 Pfs*61 | c.322C>T; p.R108* (mosaic 15% in blood) | c.2207_2210del; p.T736Ifs*43 | c.2663dup; p.L889Pfs*11 | c.5622C>A; p.Y1874* | c.6169C>T; p.Q2057* | c.4018C>T; p.Q1340X (mosaic 31.58% in blood) | c.2224C>T; p.Q742X | NA |
| X‐inactivation | NA | NA | 99:1 | NA | 97:3 | 89:11 | 99:1 | NA | 97:3 | ND | 94:6 | 100:0 | NA |
| Development delay | NA | NA | NA | No | No | NA | No | No | No | No | No | NA | 0/12 (0%) |
| Growth failure | + | − | + | + | + | − | − | + | + | − | + | − | 7/12 (58%) |
| Cleft lip/palate | + | + | + | + | + | + | + | + | + | + | + | + | 12/12 (100%) |
| Dysmorphic facial features | − | − | − | − | + | − | + | + | + | + | + | + | 7/12 (58%) |
| Pigmentary retinopathy | + | + | + | + | + | − | − | + | + | − | + | + | 9/12(75%) |
| Cardiac abnormalities | + | + | + | − | + | + | + | + | + | + | + | + | 11/12 (92%) |
| Biliary system anomalies | + | + | + | + | + | + | + | + | + | − | + | + | 11/12 (92%) |
| Intestinal anomalies | + | + | + | + | + | − | + | − | + | + | + | − | 9/12 (75%) |
| Genitourinary anomalies | + | + | + | + | + | + | + | + | + | − | + | + | 11/12 (92%) |
Note: Cardiac anomalies including aortic coarctation or dilation, pulmonic stenosis, patent ductus arteriosus (PDA), carotid artery aneurysm, and partial anomalous pulmonary venous return. Biliary anomalies reported: cholestasis, congenital absence of gall bladder, choledochal cyst, biliary atresia, cholangiocarcinoma. Intestinal anomalies reported: malrotation, Meckel's diverticulum, imperforate anus, constipation. GU anomalies reported: hydronephrosis, megaureter, vaginal atresia, bladder exstrophy, ectopic ureters.
Growth failure due to growth hormone deficiency.